BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vaillant A. REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection. ACS Infect Dis 2019;5:675-87. [PMID: 30199230 DOI: 10.1021/acsinfecdis.8b00156] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Vaillant A. Clarifying the Chemistry, Activity, and Safety of Nucleic Acid Polymers. Gastroenterology 2021;160:1427. [PMID: 32931787 DOI: 10.1053/j.gastro.2020.07.061] [Reference Citation Analysis]
2 Boulon R, Blanchet M, Lemasson M, Vaillant A, Labonté P. Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro. Antiviral Res 2020;183:104853. [PMID: 32585322 DOI: 10.1016/j.antiviral.2020.104853] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
3 Kadelka S, Dahari H, Ciupe SM. Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection. Sci Rep 2021;11:200. [PMID: 33420293 DOI: 10.1038/s41598-020-80594-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
5 Yurdaydin C. New treatment options for delta virus: Is a cure in sight? J Viral Hepat. 2019;26:618-626. [PMID: 30771261 DOI: 10.1111/jvh.13081] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
6 Zhang BY, Chai DP, Wu YH, Qiu LP, Zhang YY, Ye ZH, Yu XP. Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors. Curr Drug Targets 2019;20:1636-51. [PMID: 31362671 DOI: 10.2174/1389450120666190729115646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Alexopoulou A, Vasilieva L, Karayiannis P. New Approaches to the Treatment of Chronic Hepatitis B. J Clin Med 2020;9:E3187. [PMID: 33019573 DOI: 10.3390/jcm9103187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Mentha N, Clément S, Negro F, Alfaiate D. A review on hepatitis D: From virology to new therapies. J Adv Res 2019;17:3-15. [PMID: 31193285 DOI: 10.1016/j.jare.2019.03.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
9 Taylor JM. Infection by Hepatitis Delta Virus. Viruses. 2020;12. [PMID: 32560053 DOI: 10.3390/v12060648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
10 Gençdal G, Yurdaydin C. Developing New Therapies for Delta Hepatitis: The Race Is On. Hepatol Commun 2021;5:556-8. [PMID: 33860114 DOI: 10.1002/hep4.1685] [Reference Citation Analysis]
11 Shekhtman L, Cotler SJ, Hershkovich L, Uprichard SL, Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Dittmer U, Vaillant A, Dahari H. Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Sci Rep 2020;10:7837. [PMID: 32398799 DOI: 10.1038/s41598-020-64122-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
12 Vaillant A. HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic Hepatitis B Virus Infection. ACS Infect Dis 2021;7:1351-68. [PMID: 33302622 DOI: 10.1021/acsinfecdis.0c00638] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
13 Vaillant A; REP 401 study authors. Reply. Gastroenterology 2021;160:967-8. [PMID: 32971136 DOI: 10.1053/j.gastro.2020.09.020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Mak LY, Seto WK, Yuen MF. Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. Viruses 2021;13:1169. [PMID: 34207458 DOI: 10.3390/v13061169] [Reference Citation Analysis]
15 Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. Ther Adv Infect Dis 2020;7:2049936120965027. [PMID: 33117536 DOI: 10.1177/2049936120965027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Usman Z, Mijočević H, Karimzadeh H, Däumer M, Al-Mathab M, Bazinet M, Frishman D, Vaillant A, Roggendorf M. Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg-positive chronic HBV infection. J Viral Hepat 2019;26:1454-64. [PMID: 31323705 DOI: 10.1111/jvh.13180] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
17 Durantel D, Asselah T. Nucleic Acid Polymers are Effective in Targeting Hepatitis B Surface Antigen, but More Trials Are Needed. Gastroenterology 2020;158:2051-4. [DOI: 10.1053/j.gastro.2020.04.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ma Z, Zhang E, Gao S, Xiong Y, Lu M. Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response. Front Immunol 2019;10:2308. [PMID: 31608073 DOI: 10.3389/fimmu.2019.02308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
19 Vaillant A. Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development? Viruses 2022;14:1193. [DOI: 10.3390/v14061193] [Reference Citation Analysis]
20 Smolders EJ, Burger DM, Feld JJ, Kiser JJ. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther. 2020;51:231-243. [PMID: 31840863 DOI: 10.1111/apt.15581] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
21 Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut 2021;70:1782-94. [PMID: 34103404 DOI: 10.1136/gutjnl-2020-323888] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 32.0] [Reference Citation Analysis]
22 Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Krawczyk A, Vaillant A. Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy. J Viral Hepat 2021;28:817-25. [PMID: 33556206 DOI: 10.1111/jvh.13483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A-E. Adv Ther 2022;39:1524-52. [PMID: 35220557 DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
24 Loglio A, Viganò M, Lampertico P. Novel Therapies That May Cure Chronic Hepatitis B Virus. Clin Liver Dis 2021;25:875-99. [PMID: 34593159 DOI: 10.1016/j.cld.2021.07.001] [Reference Citation Analysis]
25 Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020;73:409-422. [PMID: 32333923 DOI: 10.1016/j.jhep.2020.04.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
26 Kuroki A, Tay J, Lee GH, Yang YY. Broad-Spectrum Antiviral Peptides and Polymers. Adv Healthc Mater 2021;10:e2101113. [PMID: 34599850 DOI: 10.1002/adhm.202101113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
27 Turon-Lagot V, Saviano A, Schuster C, Baumert TF, Verrier ER. Targeting the Host for New Therapeutic Perspectives in Hepatitis D. J Clin Med 2020;9:E222. [PMID: 31947588 DOI: 10.3390/jcm9010222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Blanchet M, Sinnathamby V, Vaillant A, Labonté P. Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells. Antiviral Res 2019;164:97-105. [PMID: 30771404 DOI: 10.1016/j.antiviral.2019.02.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
29 Mijočević H, Karimzadeh H, Seebach J, Usman Z, Al-Mahtab M, Bazinet M, Vaillant A, Roggendorf M. Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays. J Viral Hepat 2019;26:485-95. [PMID: 30450662 DOI: 10.1111/jvh.13044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Zhang Z, Urban S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. Journal of Hepatology 2021;74:686-99. [DOI: 10.1016/j.jhep.2020.11.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
31 Bassit L, Ono SK, Schinazi RF. Moving Fast Toward Hepatitis B Virus Elimination. Adv Exp Med Biol 2021;1322:115-38. [PMID: 34258739 DOI: 10.1007/978-981-16-0267-2_5] [Reference Citation Analysis]
32 Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Krawczyk A, Vaillant A. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. Gastroenterology 2020;158:2180-94. [PMID: 32147484 DOI: 10.1053/j.gastro.2020.02.058] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 24.5] [Reference Citation Analysis]
33 Vaillant A. Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. Viruses 2021;13:745. [PMID: 33922828 DOI: 10.3390/v13050745] [Reference Citation Analysis]
34 Michelet M, Alfaiate D, Chardès B, Pons C, Faure-dupuy S, Engleitner T, Farhat R, Riedl T, Legrand A, Rad R, Rivoire M, Zoulim F, Heikenwälder M, Salvetti A, Durantel D, Lucifora J. Inducers of the NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in vitro. JHEP Reports 2022;4:100415. [DOI: 10.1016/j.jhepr.2021.100415] [Reference Citation Analysis]
35 Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, Gersch J, Holzmayer V, Elsner C, Krawczyk A, Kuhns MC, Cloherty G, Dittmer U, Vaillant A. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection. Hepatol Commun 2021;5:189-202. [PMID: 33553968 DOI: 10.1002/hep4.1633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]